KUALA LUMPUR, March 19 (Bernama) -- Curia Global Inc (Curia), a contract research, development and manufacturing organisation (CDMO), has announced the expansion of its sterile fill-finish facility in Glasgow, United Kingdom, and provided updates on its ongoing expansion in Albuquerque, New Mexico.
Curia chief executive officer, Philip Macnabb in a statement emphasised that the Glasgow investment reflects Curia’s commitment to being a comprehensive partner for clinical development, particularly in response to growing demand for increased capacity from clinical-stage clients.
The Glasgow facility will be equipped with an integrated, isolator-based vial filling line and lyophiliser, enhancing its capabilities in handling highly potent drug products and more than doubling its current good manufacturing practice (GMP) batch size.
The expansion will strengthen Curia’s expertise in sterile injectable product development, covering pre-formulation, clinical phases and commercial manufacturing.
The facility’s new capacity will allow batch sizes of up to 20,000 vials, with robotic, lossless filling technology capable of operating five times faster than the current capabilities. The additional lyophiliser will also provide greater scalability for clinical-stage clients and facilitate small-volume commercial fills, while normal operations continue during the expansion.
The Glasgow expansion is part of a broader initiative that includes a US$200 million investment in a multi-year expansion at Curia’s Albuquerque facility. The project will add two isolated filling lines, increasing the manufacturing space by over 70,000 square feet to support phase III clinical and commercial production. (US$1=RM4.44)
A VarioSys Flex Line, suitable for small-scale biologics and non-potent small molecules, is currently undergoing commissioning. Additionally, a high-speed vial line, equipped with two autoloaded freeze dryers, automated vial inspection, and packaging for 2R to 30R vials, is set to begin commissioning in the third quarter of this year.
Curia’s global network of sterile fill-finish facilities also includes clinical development and manufacturing sites in Camarillo and Thousand Oaks, California, as well as commercial and clinical manufacturing capabilities in Burlington, Massachusetts.
-- BERNAMA
